5 terminated, 2 completed, 2 unknown, 1 not yet recruiting. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 5, Completed 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Relapsed or Refractory Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 80 | 2026-10-20 | 2026-09-03 |
| A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms NC525 - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | NextCure, Inc. | 28 | 2023-02-28 | 2026-01-28 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Mitoxantrone liposome, Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Hui Zeng | 70 | 2022-07-21 | 2022-08-30 |
| A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) MK-0482 - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 13 | 2021-09-26 | 2025-05-21 |
| Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Venetoclax and pegcrisantaspase - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Completed | University of Maryland, Baltimore | 27 | 2021-03-10 | 2025-10-07 |
| Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia AMG 330, Pembrolizumab - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 1 | 2020-09-29 | 2024-03-08 |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML PHI-101 - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Unknown | Seoul National University Hospital | 42 | 2020-06-08 | 2021-04-20 |
| A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation ivosidenib - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Completed | CStone Pharmaceuticals | 30 | 2019-11-12 | 2023-02-13 |
| Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia S65487- initial scheme, S65487 - alternative scheme - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | Institut de Recherches Internationales Servier | 60 | 2019-07-17 | 2024-10-16 |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia AMG 176, Azacitidine, Itraconazole - Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 141 | 2016-06-13 | 2025-07-09 |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia VS-4718 - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Withdrawn | Verastem, Inc. | 2017-01-27 |
Leukemia, Myeloid, Acute (11) · Recurrence (11) · Leukemia (3) · Leukemia, Myelomonocytic, Chronic (2) · Multiple Myeloma (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasms, Plasma Cell (1)
Disease Attributes (11) · Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Leukemia, Myeloid (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Leukemia (8) · Chronic Disease (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Blood Protein Disorders (2) · Bone Marrow Diseases (2)
venetoclax (2) · AMG 330 (1) · Azacitidine (1) · Itraconazole (1) · PHI-101 (1) · PND 1186 (1) · ivosidenib (1) · pembrolizumab (1) · tapotoclax (1)
Amgen (2) · CStone Pharmaceuticals (1) · Hui Zeng (1) · Institut de Recherches Internationales Servier (1) · Merck Sharp & Dohme LLC (1) · NextCure, Inc. (1) · Seoul National University Hospital (1) · Servier (1) · University of Maryland, Baltimore (1) · Verastem, Inc. (1)
United States (5) · Australia (2) · China (2) · Spain (2) · Canada (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · South Korea (1) · United Kingdom (1)
Hagop Youssoufian, MD (1) · Han Myint, MD (1) · Hui Zeng, M.D (1) · Sung-Soo Yoon, MD. PhD (1) · Vu Duong, MD (1)
2015 (1), 2018 (1), 2023 (1), 2025 (1)